Ratings by JPMorgan (Anupam Rama)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/22/2024 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/22/2024 | CytomX Therapeutics | CTMX | Upgrade | Neutral (Underweight) |
1.73 (1.60) |
-7.51% | Details | |
| 4/17/2024 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2024 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2024 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/1/2024 | AnaptysBio | ANAB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/1/2024 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/27/2024 | Rapt Therapeutics | RAPT | Maintain | Neutral (N/A) |
|
Details | ||
| 3/27/2024 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 3/26/2024 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2024 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2024 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2024 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2024 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2024 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2024 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2024 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2024 | Annexon Biosciences | ANNX | Upgrade | Overweight (Neutral) |
5.49 (4.59) |
-16.39% | Details | |
| 2/27/2024 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/21/2024 | Rapt Therapeutics | RAPT | Downgrade | Neutral (Overweight) |
25.97 (7.80) |
-69.97% | Details | |
| 2/1/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/22/2024 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/22/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2024 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2024 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 12/22/2023 | Allovir Inc. | ALVR | Downgrade | Underweight (Overweight) |
2.33 (0.80) |
-65.67% | Details | |
| 12/8/2023 | Cogent | COGT | New Coverage | Overweight (N/A) |
8.60 (6.01) |
-30.12% | Details | |
| 12/6/2023 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/30/2023 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/30/2023 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/30/2023 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/30/2023 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/22/2023 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/22/2023 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2023 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2023 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2023 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2023 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2023 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/6/2023 | G1 Therapeutics | GTHX | Downgrade | Underweight (Neutral) |
1.14 (3.86) |
238.6% | Details | |
| 10/6/2023 | Apellis Pharmaceuticals | APLS | Upgrade | Overweight (Neutral) |
37.62 (47.93) |
27.41% | Details | |
| 10/5/2023 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/29/2023 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 9/29/2023 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2023 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/17/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/17/2023 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2023 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2023 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2023 | Generation Bio | GBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 8/10/2023 | Rallybio Corp. | RLYB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2023 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2023 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Overweight) |
24.22 (47.93) |
97.89% | Details | |
| 7/25/2023 | Kodiak Sciences Inc. | KOD | Downgrade | Underweight (Neutral) |
7.29 (3.19) |
-56.24% | Details | |
| 7/21/2023 | Travere Therapeutics | TVTX | New Coverage | Overweight (N/A) |
15.45 (5.39) |
-65.11% | Details | |
| 7/20/2023 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/17/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2023 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2023 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/25/2023 | Annexon Biosciences | ANNX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/24/2023 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/24/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2023 | AnaptysBio | ANAB | Upgrade | Neutral (Underweight) |
18.93 (18.87) |
-0.32% | Details | |
| 5/15/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2023 | Rallybio Corp. | RLYB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2023 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2023 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2023 | AnaptysBio | ANAB | Maintain | Underweight (N/A) |
|
Details | ||
| 4/12/2023 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/4/2023 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/21/2023 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/21/2023 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 3/16/2023 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2023 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2023 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/8/2023 | Rallybio Corp. | RLYB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2023 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2023 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2023 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2023 | G1 Therapeutics | GTHX | Upgrade | Neutral (Underweight) |
6.57 (3.86) |
-41.25% | Details | |
| 1/20/2023 | Cyteir Therapeutics | CYT | Downgrade | Neutral (Overweight) |
1.53 (3.02) |
97.39% | Details | |
| 1/3/2023 | Syndax Pharmaceuticals | SNDX | New Coverage | Overweight (N/A) |
24.76 (20.57) |
-16.92% | Details | |
| 12/12/2022 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2022 | Rallybio Corp. | RLYB | New Coverage | Overweight (N/A) |
4.76 (1.65) |
-65.34% | Details | |
| 12/6/2022 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2022 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2022 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2022 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2022 | AnaptysBio | ANAB | Maintain | Underweight (N/A) |
|
Details | ||
| 11/16/2022 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/16/2022 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 11/16/2022 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2022 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2022 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2022 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2022 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2022 | CytomX Therapeutics | CTMX | Downgrade | Underweight (Overweight) |
1.23 (1.60) |
30.08% | Details | |
| 11/10/2022 | Elevation Oncology | ELEV | Downgrade | Underweight (Neutral) |
0.94 (3.65) |
288.3% | Details | |
| 11/9/2022 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2022 | G1 Therapeutics | GTHX | Maintain | Underweight (N/A) |
|
Details | ||
| 11/8/2022 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2022 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2022 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 9/30/2022 | Solid Biosciences | SLDB | Upgrade | Neutral (Underweight) |
0.47 (8.54) |
1717.02% | Details | |
| 9/29/2022 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 9/6/2022 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2022 | Atara Biotherapeutics | ATRA | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2022 | Elevation Oncology | ELEV | Downgrade | Neutral (Overweight) |
1.33 (3.65) |
174.44% | Details | |
| 8/2/2022 | Ultragenyx Pharma | RARE | New Coverage | Overweight (N/A) |
53.28 (43.85) |
-17.7% | Details | |
| 8/2/2022 | Sage Therapeutics | SAGE | New Coverage | Overweight (N/A) |
34.41 (13.58) |
-60.53% | Details | |
| 8/2/2022 | CytomX Therapeutics | CTMX | New Coverage | Overweight (N/A) |
1.43 (1.60) |
11.89% | Details | |
| 7/13/2022 | Atara Biotherapeutics | ATRA | Downgrade | Neutral (Overweight) |
8.66 (0.70) |
-91.92% | Details | |
| 7/12/2022 | Vera Therapeutics | VERA | New Coverage | Overweight (N/A) |
14.69 (38.69) |
163.38% | Details | |
| 5/27/2022 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2022 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2022 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | ChemoCentryx | CCXI | Maintain | Neutral (N/A) |
|
Details | ||
| 5/5/2022 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/28/2022 | Atara Biotherapeutics | ATRA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2022 | AnaptysBio | ANAB | Maintain | Underweight (N/A) |
|
Details | ||
| 3/15/2022 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2022 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2022 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2022 | Aeglea Biotherapeutics | AGLE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/8/2022 | Passage Bio Inc. | PASG | Downgrade | Neutral (Overweight) |
2.93 (1.22) |
-58.36% | Details | |
| 3/3/2022 | ChemoCentryx | CCXI | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2022 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2022 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2022 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2022 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2022 | Theravance Biopharma | TBPH | Maintain | Neutral (N/A) |
|
Details | ||
| 2/24/2022 | Kodiak Sciences Inc. | KOD | Downgrade | Neutral (Overweight) |
9.86 (3.19) |
-67.65% | Details | |
| 2/16/2022 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/14/2022 | Generation Bio | GBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 2/2/2022 | Kodiak Sciences Inc. | KOD | Upgrade | Overweight (Neutral) |
58.70 (3.19) |
-94.57% | Details | |
| 12/14/2021 | Generation Bio | GBIO | Downgrade | Neutral (Overweight) |
13.90 (3.01) |
-78.35% | Details | |
| 12/10/2021 | Cytokinetics | CYTK | New Coverage | Overweight (N/A) |
37.05 (64.80) |
74.9% | Details | |
| 12/9/2021 | Rapt Therapeutics | RAPT | New Coverage | Overweight (N/A) |
30.80 (7.80) |
-74.68% | Details | |
| 11/24/2021 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 11/19/2021 | BioAtla Inc. | BCAB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2021 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2021 | Neurocrine Bio. | NBIX | Upgrade | Overweight (Neutral) |
87.78 (137.76) |
56.94% | Details | |
| 11/16/2021 | Orchard Therapeutics | ORTX | Downgrade | Underweight (Neutral) |
1.77 (16.70) |
843.5% | Details | |
| 11/9/2021 | Oyster Point Pharma | OYST | Downgrade | Neutral (Overweight) |
14.12 (11.17) |
-20.89% | Details | |
| 11/5/2021 | Theravance Biopharma | TBPH | Upgrade | Neutral (Underweight) |
8.08 (9.14) |
13.12% | Details | |
| 11/5/2021 | Sarepta Therapeutics | SRPT | Upgrade | Overweight (Neutral) |
86.53 (127.39) |
47.22% | Details | |
| 11/4/2021 | G1 Therapeutics | GTHX | Downgrade | Underweight (Neutral) |
16.16 (3.86) |
-76.11% | Details | |
| 11/2/2021 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/25/2021 | Vir Biotechnology | VIR | Upgrade | Neutral (Underweight) |
39.93 (7.63) |
-80.89% | Details | |
| 10/12/2021 | Protagonist Therapeutics | PTGX | Upgrade | Overweight (Neutral) |
18.24 (24.66) |
35.2% | Details | |
| 10/11/2021 | ChemoCentryx | CCXI | Upgrade | Neutral (Underweight) |
38.41 (51.99) |
35.36% | Details | |
| 9/30/2021 | G1 Therapeutics | GTHX | Downgrade | Neutral (Overweight) |
15.40 (3.86) |
-74.94% | Details | |
| 9/30/2021 | Amicus Therapeutics | FOLD | Upgrade | Overweight (Neutral) |
10.18 (10.17) |
-0.1% | Details | |
| 9/20/2021 | Protagonist Therapeutics | PTGX | Downgrade | Neutral (Overweight) |
46.13 (24.66) |
-46.54% | Details | |
| 9/15/2021 | Theravance Biopharma | TBPH | Downgrade | Underweight (Overweight) |
8.04 (9.14) |
13.68% | Details | |
| 9/8/2021 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/7/2021 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/26/2021 | ChemoCentryx | CCXI | Maintain | Underweight (N/A) |
|
Details | ||
| 8/25/2021 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2021 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2021 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2021 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2021 | Aeglea Biotherapeutics | AGLE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2021 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2021 | Nuvalent | NUVL | New Coverage | Overweight (N/A) |
26.40 (66.07) |
150.27% | Details | |
| 8/18/2021 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2021 | BioAtla Inc. | BCAB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2021 | Orchard Therapeutics | ORTX | Downgrade | Neutral (Overweight) |
2.69 (16.70) |
520.82% | Details | |
| 8/17/2021 | Oyster Point Pharma | OYST | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2021 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2021 | Erasca Inc | ERAS | New Coverage | Overweight (N/A) |
20.99 (1.88) |
-91.04% | Details | |
| 8/5/2021 | Sarepta Therapeutics | SRPT | Upgrade | Neutral (Underweight) |
69.04 (127.39) |
84.52% | Details | |
| 8/2/2021 | Infinity Pharmaceutical | INFI | Upgrade | Overweight (Neutral) |
2.33 (0.04) |
-98.28% | Details | |
| 7/20/2021 | Elevation Oncology | ELEV | New Coverage | Overweight (N/A) |
12.10 (3.65) |
-69.83% | Details | |
| 7/13/2021 | Cytier Therapeutics | CYT | New Coverage | Overweight (N/A) |
18.89 (3.02) |
-84.01% | Details | |
| 7/2/2021 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/30/2021 | Orchard Therapeutics | ORTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/21/2021 | Day One Biopharmaceuticals | DAWN | New Coverage | Overweight (N/A) |
19.46 (13.21) |
-32.12% | Details | |
| 6/11/2021 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/2/2021 | Constellation Pharmaceuticals | CNST | Downgrade | Neutral (Overweight) |
20.24 (33.99) |
67.93% | Details | |
| 6/1/2021 | Orchard Therapeutics | ORTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2021 | iTeos Therapeutics | ITOS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2021 | Atara Biotherapeutics | ATRA | Upgrade | Overweight (Neutral) |
13.91 (0.70) |
-94.97% | Details | |
| 5/12/2021 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2021 | Oyster Point Pharma | OYST | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2021 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 5/11/2021 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | ChemoCentryx | CCXI | Downgrade | Underweight (Neutral) |
27.49 (51.99) |
89.12% | Details | |
| 5/6/2021 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/6/2021 | Theravance Biopharma | TBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2021 | AnaptysBio | ANAB | Maintain | Underweight (N/A) |
|
Details | ||
| 5/6/2021 | Atara Biotherapeutics | ATRA | Maintain | Neutral (N/A) |
|
Details | ||
| 4/16/2021 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2021 | CytomX Therapeutics | CTMX | New Coverage | Overweight (N/A) |
7.94 (1.60) |
-79.85% | Details | |
| 3/23/2021 | Frequency Therapeutics | FREQ | Downgrade | Underweight (Overweight) |
36.29 (0.30) |
-99.17% | Details | |
| 3/19/2021 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/19/2021 | Idera Pharmaceuticals | IDRA | Downgrade | Neutral (Overweight) |
5.13 (0.43) |
-91.62% | Details | |
| 3/8/2021 | AnaptysBio | ANAB | Downgrade | Underweight (Overweight) |
29.47 (18.87) |
-35.97% | Details | |
| 3/2/2021 | Orchard Therapeutics | ORTX | New Coverage | Overweight (N/A) |
6.97 (16.70) |
139.6% | Details | |
| 2/22/2021 | BridgeBio Pharma | BBIO | New Coverage | Overweight (N/A) |
63.85 (24.33) |
-61.9% | Details | |
| 2/16/2021 | G1 Therapeutics | GTHX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2021 | AnaptysBio | ANAB | Upgrade | Overweight (Neutral) |
29.61 (29.47) |
-0.47% | Details | |
| 2/5/2021 | Infinity Pharmaceutical | INFI | Upgrade | Neutral (Underweight) |
3.70 (0.04) |
-98.92% | Details | |
| 1/27/2021 | Frequency Therapeutics | FREQ | Upgrade | Overweight (Neutral) |
37.83 (36.29) |
-4.07% | Details | |
| 1/27/2021 | Vir Biotechnology | VIR | Downgrade | Underweight (Neutral) |
44.39 (7.63) |
-82.81% | Details | |
| 1/8/2021 | Sarepta Therapeutics | SRPT | Downgrade | Underweight (Overweight) |
168.95 (127.39) |
-24.6% | Details | |
| 1/4/2021 | Passage Bio Inc. | PASG | Upgrade | Overweight (Neutral) |
25.57 (1.22) |
-95.23% | Details | |
| 11/30/2020 | Kodiak Sciences Inc. | KOD | Downgrade | Neutral (Overweight) |
132.20 (3.19) |
-97.59% | Details | |
| 11/10/2020 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/6/2020 | Oyster Point Pharma | OYST | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2020 | ChemoCentryx | CCXI | Downgrade | Neutral (Overweight) |
52.44 (51.99) |
-0.86% | Details | |
| 10/5/2020 | MyoKardia | MYOK | Downgrade | Neutral (Overweight) |
139.60 (224.91) |
61.11% | Details | |
| 9/11/2020 | Vir Biotechnology | VIR | Upgrade | Neutral (Underweight) |
30.17 (7.63) |
-74.71% | Details | |
| 8/25/2020 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2020 | Allovir Inc. | ALVR | New Coverage | Overweight (N/A) |
30.85 (0.80) |
-97.41% | Details | |
| 8/17/2020 | Annexon Biosciences | ANNX | New Coverage | Overweight (N/A) |
26.17 (4.59) |
-82.46% | Details | |
| 8/17/2020 | iTeos Therapeutics | ITOS | New Coverage | Overweight (N/A) |
31.40 (10.60) |
-66.24% | Details | |
| 8/14/2020 | Passage Bio Inc. | PASG | Downgrade | Neutral (Overweight) |
14.77 (25.57) |
73.12% | Details | |
| 8/13/2020 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2020 | ChemoCentryx | CCXI | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2020 | Generation Bio | GBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2020 | MyoKardia | MYOK | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2020 | Oyster Point Pharma | OYST | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2020 | Neurocrine Bio. | NBIX | Downgrade | Neutral (Overweight) |
120.36 (137.76) |
14.46% | Details | |
| 7/17/2020 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2020 | Ideaya Biosciences | IDYA | Upgrade | Overweight (Neutral) |
13.34 (38.62) |
189.51% | Details | |
| 7/7/2020 | Generation Bio | GBIO | New Coverage | Overweight (N/A) |
19.56 (13.90) |
-28.94% | Details | |
| 7/7/2020 | Theravance Biopharma | TBPH | New Coverage | Overweight (N/A) |
20.52 (8.04) |
-60.82% | Details | |
| 6/29/2020 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2020 | Frequency Therapeutics | FREQ | Downgrade | Neutral (Overweight) |
16.99 (37.83) |
122.66% | Details | |
| 5/14/2020 | Eidos Therapeutics | EIDX | Downgrade | Neutral (Overweight) |
41.09 (122.21) |
197.42% | Details | |
| 5/7/2020 | Alnylam Pharmaceuticals | ALNY | Downgrade | Neutral (Overweight) |
141.23 (143.71) |
1.76% | Details | |
| 5/1/2020 | Mirati Therapeutics | MRTX | Upgrade | Overweight (Neutral) |
87.80 (58.70) |
-33.14% | Details | |
| 3/24/2020 | Passage Bio Inc. | PASG | New Coverage | Overweight (N/A) |
9.79 (1.22) |
-87.54% | Details | |
| 3/20/2020 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/19/2020 | Vir Biotechnology | VIR | Downgrade | Underweight (Neutral) |
50.26 (7.63) |
-84.82% | Details | |
| 3/18/2020 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2020 | Kodiak Sciences Inc. | KOD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2020 | Mirati Therapeutics | MRTX | Upgrade | Neutral (Underweight) |
86.58 (87.80) |
1.41% | Details | |
| 3/2/2020 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2020 | ChemoCentryx | CCXI | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2020 | Agios Pharma | AGIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2020 | Vir Biotechnology | VIR | Downgrade | Neutral (Overweight) |
26.63 (50.26) |
88.73% | Details | |
| 12/24/2019 | Kodiak Sciences Inc. | KOD | New Coverage | Overweight (N/A) |
67.03 (3.19) |
-95.24% | Details | |
| 12/24/2019 | Y-mAbs Therapeutics | YMAB | New Coverage | Overweight (N/A) |
31.75 (14.84) |
-53.26% | Details | |
| 12/5/2019 | Audentes Therapeutics | BOLD | Downgrade | Neutral (Overweight) |
59.30 (12.07) |
-79.65% | Details | |
| 11/26/2019 | ChemoCentryx | CCXI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/25/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/22/2019 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2019 | AnaptysBio | ANAB | Downgrade | Underweight (Overweight) |
36.16 (18.87) |
-47.82% | Details | |
| 11/8/2019 | Atara Biotherapeutics | ATRA | Downgrade | Neutral (Overweight) |
12.16 (0.70) |
-94.24% | Details | |
| 11/5/2019 | Vir Biotechnology | VIR | New Coverage | Overweight (N/A) |
15.00 (7.63) |
-49.13% | Details | |
| 10/28/2019 | Frequency Therapeutics | FREQ | New Coverage | Overweight (N/A) |
14.05 (0.30) |
-97.86% | Details | |
| 10/16/2019 | Mirati Therapeutics | MRTX | Maintain | Underweight (N/A) |
|
Details | ||
| 10/8/2019 | Spring Works Therapeutics | SWTX | New Coverage | Overweight (N/A) |
18.15 (44.20) |
143.53% | Details | |
| 10/3/2019 | Dova Pharmaceuticals Inc | DOVA | Upgrade | Neutral (Underweight) |
27.87 (28.04) |
0.61% | Details | |
| 9/12/2019 | ChemoCentryx | CCXI | Upgrade | Overweight (Neutral) |
7.59 (51.99) |
584.98% | Details | |
| 8/8/2019 | G1 Therapeutics | GTHX | Upgrade | Overweight (Neutral) |
23.48 (3.86) |
-83.56% | Details | |
| 8/2/2019 | Mirati Therapeutics | MRTX | New Coverage | Underweight (N/A) |
105.80 (58.70) |
-44.52% | Details | |
| 7/12/2019 | Replimune Group | REPL | Upgrade | Overweight (Neutral) |
13.93 (6.15) |
-55.85% | Details | |
| 7/12/2019 | Apellis Pharmaceuticals | APLS | Upgrade | Overweight (Neutral) |
26.88 (47.93) |
78.31% | Details | |
| 4/22/2019 | Neurocrine Bio. | NBIX | Upgrade | Overweight (Neutral) |
78.43 (137.76) |
75.65% | Details | |
| 4/17/2019 | Mirati Therapeutics | MRTX | New Coverage | Neutral (N/A) |
65.18 (105.80) |
62.32% | Details | |
| 3/21/2019 | Aeglea Biotherapeutics | AGLE | New Coverage | Overweight (N/A) |
8.25 (12.01) |
45.58% | Details | |
| 3/1/2019 | Rigel Pharmaceuticals | RIGL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2019 | Eidos Therapeutics | EIDX | Upgrade | Overweight (Neutral) |
17.51 (122.21) |
597.94% | Details | |
| 2/21/2019 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2019 | Replimune Group | REPL | Downgrade | Neutral (Overweight) |
10.45 (13.93) |
33.3% | Details | |
| 1/23/2019 | Neurocrine Bio. | NBIX | Downgrade | Neutral (Overweight) |
91.53 (78.43) |
-14.31% | Details | |
| 1/23/2019 | La Jolla Pharma | LJPC | Upgrade | Neutral (Underweight) |
6.30 (6.22) |
-1.27% | Details | |
| 1/23/2019 | G1 Therapeutics | GTHX | Downgrade | Neutral (Overweight) |
20.13 (23.48) |
16.64% | Details | |
| 1/23/2019 | Eidos Therapeutics | EIDX | Downgrade | Neutral (Overweight) |
12.65 (17.51) |
38.42% | Details | |
| 1/23/2019 | Dova Pharmaceuticals Inc | DOVA | Downgrade | Underweight (Overweight) |
8.23 (27.87) |
238.64% | Details | |
| 1/23/2019 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Overweight) |
13.44 (26.88) |
100% | Details | |
| 12/12/2018 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/26/2018 | Orchard Therapeutics | ORTX | New Coverage | Overweight (N/A) |
16.04 (16.70) |
4.11% | Details | |
| 11/26/2018 | Audentes Therapeutics | BOLD | New Coverage | Overweight (N/A) |
24.01 (59.30) |
146.98% | Details | |
| 11/21/2018 | AnaptysBio | ANAB | New Coverage | Overweight (N/A) |
67.80 (36.16) |
-46.67% | Details | |
| 11/12/2018 | Infinity Pharmaceutical | INFI | Downgrade | Underweight (Neutral) |
2.41 (0.04) |
-98.34% | Details | |
| 10/8/2018 | Dynavax Technologies | DVAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/27/2018 | Eidos Therapeutics | EIDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2018 | Idera Pharmaceuticals | IDRA | New Coverage | Overweight (N/A) |
7.39 (0.43) |
-94.18% | Details | |
| 8/14/2018 | Replimune Group | REPL | New Coverage | Overweight (N/A) |
16.91 (10.45) |
-38.2% | Details | |
| 8/14/2018 | ChemoCentryx | CCXI | Downgrade | Neutral (Overweight) |
11.95 (7.59) |
-36.49% | Details | |
| 8/13/2018 | Constellation Pharmaceuticals | CNST | New Coverage | Overweight (N/A) |
9.87 (20.24) |
105.07% | Details |
